Abstract
The primary screening by automated computational pathology algorithms of the presence or absence of adenocarcinoma in biopsy specimens (e.g., endoscopic biopsy, transbronchial lung biopsy, and needle biopsy) of possible primary organs (e.g., stomach, colon, lung, and breast) and radical lymph node dissection specimen is very useful and should be a powerful tool to assist surgical pathologists in routine histopathological diagnostic workflow. In this paper, we trained multi-organ deep learning models to classify adenocarcinoma in biopsy and radical lymph node dissection specimens whole slide images (WSIs). We evaluated the models on seven independent test sets (stomach, colon, lung, breast, lymph nodes) to demonstrate the feasibility in multiorgan and lymph nodes specimens from different medical institutions and international public datasets, achieving receiver operating characteristic areas under the curves (ROC-AUCs) in the range of 0.91-0.99.
Competing Interest Statement
M.T. and F.K. are employees of Medmain Inc.
Funding Statement
The authors received no financial supports for the research, authorship, and publication of this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The experimental protocol was approved by the ethical board of International University of Health and Welfare (No. 19-Im-007) and Kamachi Group Hospitals (No. 173). All research activities complied with all relevant ethical regulations and were performed in accordance with relevant guidelines and regulations in the all hospitals mentioned above. Informed consent to use histopathological samples and pathological diagnostic reports for research purposes had previously been obtained from all patients prior to the surgical procedures at all hospitals, and the opportunity for refusal to participate in research had been guaranteed by an opt-out manner.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos